Ethical, Legal, and Social Assessment of AI-Based Technologies for Prevention and Diagnosis of Rare Diseases in Health Technology Assessment Processes
Abstract
:1. Introduction
- ▪ Modular structure: the model is divided into nine domains—health problem and current use, technical characteristics, safety, clinical effectiveness, economic evaluation, ethical analysis, organizational aspects, legal aspects, and patient/social aspects—allowing for flexible and targeted assessments;
- ▪ Standardization: it promotes consistency and comparability in HTA reports across different countries, facilitating knowledge sharing and cross-border applicability;
- ▪ Comprehensive approach: beyond clinical and economic factors, the model integrates ethical, social, and organizational considerations to provide a multidimensional assessment;
- ▪ Adaptability: while structured, it remains flexible to accommodate the specific needs of different healthcare systems and regional contexts;
- ▪ Collaborative tool: it enables joint assessments by multiple HTA agencies, reducing duplication of efforts and fostering international cooperation;
- ▪ Transparency: by clearly defining domains, questions, and methodologies, the model enhances clarity in decision-making and ensures openness in the assessment process.
- ▪ Joint Clinical Assessments (JCA): the Core Model serves as the methodological foundation for JCA under the new EU HTA Regulation (EU) 2021/2282, ensuring a systematic evaluation of health technologies across Europe [8];
- ▪ Integration into national HTA processes: several European countries, including Germany, France, Italy, and Sweden, have incorporated the Core Model’s principles and structure into their national HTA frameworks [9];
- ▪ Training and capacity building: regular workshops and training sessions organized by EUnetHTA attracted representatives from various European HTA agencies, demonstrating sustained interest and application [10];
- ▪ Citations in literature and guidelines: the Core Model is frequently referenced in HTA-related publications, best practice documents, and methodological guidelines, underscoring its recognized value [11];
- ▪ Global interest and adaptation: while primarily used in Europe, the model has garnered international attention, with some HTA bodies outside the region exploring its applicability for their own assessments [12].
2. Materials and Methods
2.1. Literature Review and Data Synthesis
2.2. Focus Group Discussion
3. Results
3.1. A. What Specific Issues, Beyond Those Addressed in the EUnetHTA Core Model®, Should Be Considered in the Ethical, Legal, and Social Evaluation of Technologies Designed for Rare Diseases?
3.1.1. Ethical Issues
3.1.2. Legal Issue
3.2. B. What Specific Issues, Beyond Those Addressed in the EUnetHTA Core Model®, Should Be Considered in the Ethical, Legal, and Social Evaluation of AI-Based Technologies?
3.2.1. Ethical Issues
3.2.2. Legal Issues
3.2.3. Social Issues
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
AI | Artificial Intelligence |
CAYA | Children, adolescents and young adults |
CHM | Childhood melanoma |
HTA | Health Technology Assessment |
References
- Assasi, N.; Schwartz, L.; Tarride, J.E.; Campbell, K.; Goeree, R. Methodological Guidance Documents for Evaluation of Ethical Considerations in Health Technology Assessment: A Systematic Review. Expert Rev. Pharmacoecon. Outcomes Res. 2014, 14, 203–220. [Google Scholar] [PubMed]
- Hofmann, B.; Lysdahl, K.B.; Droste, S. Evaluation of Ethical Aspects in Health Technology Assessment: More Methods Than Applications? Expert Rev. Pharmacoecon. Outcomes Res. 2015, 15, 5–7. [Google Scholar] [CrossRef] [PubMed]
- Facey, K.M.; Ploug Hansen, H.; Single, A.N.V. Patient Involvement in Health Technology Assessment; Springer: Singapore, 2017. [Google Scholar]
- Vandemeulebroucke, T.; Denier, Y.; Mertens, E.; Gastmans, C. Which Framework to Use? A Systematic Review of Ethical Frameworks for the Screening or Evaluation of Health Technology Innovations. Sci. Eng. Ethics 2022, 28, 26. [Google Scholar] [CrossRef]
- Wagner, M.; Goetghebeur, M.M.; Ganache, I.; Demers-Payette, O.; Auclair, Y.; Olivier, C.; Arbour, S.; de Guise, M. HTA Challenges for Appraising Rare Disease Interventions Viewed Through the Lens of an Institutional Multidimensional Value Framework. Expert Rev. Pharmacoecon. Outcomes Res. 2023, 23, 143–152. [Google Scholar] [CrossRef]
- Graili, P.; Ieraci, L.; Hosseinkhah, N.; Argent-Katwala, M. Artificial Intelligence in Outcomes Research: A Systematic Scoping Review. Expert Rev. Pharmacoecon. Outcomes Res. 2021, 21, 601–623. [Google Scholar]
- EUnetHTA Joint Action 2, Work Package 8. The HTA Core Model® Version 3.0. 2016. Available online: https://web.archive.org/web/20230118032903/http://www.eunethta.eu/ (accessed on 26 December 2024).
- Imaz-Iglesia, I.; Wild, C. EUnetHTA’s Contribution to the New Legal Framework for Health Technology Assessment Cooperation in Europe. Int. J. Technol. Assess. Health Care 2022, 38, e50. [Google Scholar] [PubMed]
- Radaelli, G.; Lettieri, E.; Masella, C.; Merlino, L.; Strada, A.; Tringali, M. Implementation of EUnetHTA Core Model® in Lombardia: The VTS Framework. Int. J. Technol. Assess. Health Care 2014, 30, 105–112. [Google Scholar]
- Fuchs, S.; Olberg, B.; Panteli, D.; Busse, R. Health Technology Assessment of Medical Devices in Europe: Processes, Practices, and Methods. Int. J. Technol. Assess. Health Care 2016, 32, 246–255. [Google Scholar]
- Giuliani, G.; Chassagnol, F.; Traub, D.; Gyldmark, M.; Hebborn, A.; Ducournau, P.; Ruof, J. Leveraging EUnetHTA’s Conceptual Framework to Compare HTA Decision Drivers in France, Italy, and Germany from a Manufacturer’s Point of View. Health Econ. Rev. 2018, 8, 24. [Google Scholar]
- Ibargoyen-Roteta, N.; Galnares-Cordero, L.; Benguria-Arrate, G.; Chacón-Acevedo, K.R.; Gutiérrez-Sepulveda, M.P.; Low-Padilla, E.; De La Hoz-Siegler, I.H.; Guevara-Pérez, C.I.; Del Pozo-Pérez, Á.; Suárez, M.; et al. A Systematic Review of the Early Dialogue Frameworks Used Within Health Technology Assessment and Their Actual Adoption from HTA Agencies. Front. Public Health 2022, 10, 942230. [Google Scholar]
- Hageman, I.C.; van Rooij, I.A.L.M.; de Blaauw, I.; Trajanovska, M.; King, S.K. A Systematic Overview of Rare Disease Patient Registries: Challenges in Design, Quality Management, and Maintenance. Orphanet J. Rare Dis. 2023, 18, 106. [Google Scholar] [PubMed]
- Cerminara, S.E.; Cheng, P.; Kostner, L.; Huber, S.; Kunz, M.; Maul, J.T.; Böhm, J.S.; Dettwiler, C.F.; Geser, A.; Jakopović, C.; et al. Diagnostic Performance of Augmented Intelligence with 2D and 3D Total Body Photography and Convolutional Neural Networks in a High-Risk Population for Melanoma Under Real-World Conditions: A New Era of Skin Cancer Screening? Eur. J. Cancer 2023, 190, 112954. [Google Scholar] [CrossRef] [PubMed]
- Ferrari, A.; Brecht, I.B.; Gatta, G.; Schneider, D.T.; Orbach, D.; Cecchetto, G.; Godzinski, J.; Reguerre, Y.; Bien, E.; Stachowicz-Stencel, T.; et al. Defining and Listing Very Rare Cancers of Paediatric Age: Consensus of the Joint Action on Rare Cancers in Cooperation with the European Cooperative Study Group for Pediatric Rare Tumors. Eur. J. Cancer 2019, 110, 120–126. [Google Scholar] [CrossRef]
- De Giorgi, V.; Magnaterra, E.; Zuccaro, B.; Magi, S.; Magliulo, M.; Medri, M.; Mazzoni, L.; Venturi, F.; Silvestri, F.; Tomassini, G.M.; et al. Is Pediatric Melanoma Really That Different from Adult Melanoma? A Multicenter Epidemiological, Clinical and Dermoscopic Study. Cancers 2023, 15, 1835. [Google Scholar] [CrossRef]
- Fetters, M.D.; Curry, L.A.; Creswell, J.W. Achieving Integration in Mixed Methods Designs—Principles and Practices. Health Serv. Res. 2013, 48, 2134–2156. [Google Scholar] [CrossRef] [PubMed]
- Creswell, C.J.; Plano Clark, V.L. Designing and Conducting Mixed Methods Research; Sage Publications: Los Angeles, CA, USA, 2017. [Google Scholar]
- Skamagki, G.; King, A.; Carpenter, C.; Wåhlin, C. The Concept of Integration in Mixed Methods Research: A Step-by-Step Guide Using an Example Study in Physiotherapy. Physiother. Theory Pract. 2024, 40, 197–204. [Google Scholar]
- Dixon-Woods, M.; Cavers, D.; Agarwal, S.; Annandale, E.; Arthur, A.; Harvey, J.; Hsu, R.; Katbamna, S.; Olsen, R.; Smith, L.; et al. Conducting a Critical Interpretive Synthesis of the Literature on Access to Healthcare by Vulnerable Groups. BMC Med. Res. Meth. 2006, 6, 35. [Google Scholar] [CrossRef]
- Refolo, P.; Raimondi, C.; Battaglia, L.; Borràs, J.M.; Closa, P.; Lo Scalzo, A.; Marchetti, M.; López, S.M.; Perez, J.P.; Sampietro-Colom; et al. Policy Challenges in Ultra-Rare Cancers: Ethical, Social, and Legal Implications of Melanoma Prevention and Diagnosis in Children, Adolescents, and Young Adults. Healthcare 2025, 13, 321. [Google Scholar] [CrossRef]
- O’Brien, B.C.; Harris, I.B.; Beckman, T.J.; Reed, D.A.; Cook, D.A. Standards for Reporting Qualitative Research: A Synthesis of Recommendations. Acad. Med. 2014, 89, 1245–1251. [Google Scholar] [CrossRef]
- Nestler-Parr, S.; Korchagina, D.; Toumi, M.; Pashos, C.L.; Blanchette, C.; Molsen, E.; Morel, T.; Simoens, S.; Kaló, Z.; Gatermann, R.; et al. Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group. Value Health 2018, 21, 493–500. [Google Scholar] [CrossRef]
- Sarri, G.; Rizzo, M.; Upadhyaya, S.; Paly, V.F.; Hernandez, L. Navigating the Unknown: How to Best ‘Reflect’ Standard of Care in Indications Without a Dedicated Treatment Pathway in Health Technology Assessment Submissions. J. Comp. Eff. Res. 2024, 13, e230145. [Google Scholar]
- Farah, L.; Borget, I.; Martelli, N.; Vallee, A. Suitability of the Current Health Technology Assessment of Innovative Artificial Intelligence-Based Medical Devices: Scoping Literature Review. J. Med. Internet Res. 2024, 26, e51514. [Google Scholar] [PubMed]
- Farah, L.; Davaze-Schneider, J.; Martin, T.; Nguyen, P.; Borget, I.; Martelli, N. Are Current Clinical Studies on Artificial Intelligence-Based Medical Devices Comprehensive Enough to Support a Full Health Technology Assessment? A Systematic Review. Artif. Intell. Med. 2023, 140, 102547. [Google Scholar]
- Fasterholdt, I.; Kjølhede, T.; Naghavi-Behzad, M.; Schmidt, T.; Rautalammi, Q.T.S.; Hildebrandt, M.G.; Gerdes, A.; Barkler, A.; Kidholm, K.; Rac, V.E.; et al. Model for Assessing the Value of Artificial Intelligence in Medical Imaging (MAS-AI). Int. J. Technol. Assess. Health Care 2022, 38, e74. [Google Scholar] [CrossRef] [PubMed]
- Alami, H.; Lehoux, P.; Auclair, Y.; de Guise, M.; Gagnon, M.P.; Shaw, J.; Roy, D.; Fleet, R.; Ag Ahmed, M.A.; Fortin, J.P. Artificial Intelligence and Health Technology Assessment: Anticipating a New Level of Complexity. J. Med. Internet Res. 2020, 22, e17707. [Google Scholar]
- Sadrolashrafi, K.; Cotter, D.G. Not Your Mother’s Melanoma: Causes and Effects of Early Melanoma Diagnosis. Dermatopathology 2022, 9, 368–378. [Google Scholar] [CrossRef] [PubMed]
- Najmi, M.; Brown, A.E.; Harrington, S.R.; Farris, D.; Sepulveda, S.; Nelson, K.C. A Systematic Review and Synthesis of Qualitative and Quantitative Studies Evaluating Provider, Patient, and Health Care System-Related Barriers to Diagnostic Skin Cancer Examinations. Arch. Dermatol. Res. 2022, 314, 329–340. [Google Scholar]
- Li, H.O.; Bailey, A.J.; Grose, E.; McDonald, J.T.; Quimby, A.; Johnson-Obaseki, S.; Nessim, C. Socioeconomic Status and Melanoma in Canada: A Systematic Review. J. Cutan. Med. Surg. 2021, 25, 87–94. [Google Scholar] [CrossRef]
- Toolan, M.; Walpole, S.; Shah, K.; Kenny, J.; Jónsson, P.; Crabb, N.; Greaves, F. Environmental Impact Assessment in Health Technology Assessment: Principles, Approaches, and Challenges. Int. J. Technol. Assess. Health Care 2023, 39, e13. [Google Scholar]
- Hensher, M. Health Technology Assessment and Healthcare Environmental Sustainability: Prioritizing Effort and Maximizing Impact. Int. J. Technol. Assess. Health Care 2024, 40, e25. [Google Scholar]
- Abdallah, S.; Sharifa, M.; Almadhoun, I.K.; Khawar, M.M., Sr.; Shaikh, U.; Balabel, K.M.; Saleh, I.; Manzoor, A.; Mandal, A.K.; Ekomwereren, O.; et al. The Impact of Artificial Intelligence on Optimizing Diagnosis and Treatment Plans for Rare Genetic Disorders. Cureus 2023, 15, e46860. [Google Scholar] [CrossRef] [PubMed]
- Brereton, L.; Wahlster, P.; Mozygemba, K.; Lysdahl, K.B.; Burns, J.; Polus, S.; Tummers, M.; Refolo, P.; Sacchini, D.; Leppert, W.; et al. Stakeholder Involvement Throughout Health Technology Assessment: An Example from Palliative Care. Int. J. Technol. Assess. Health Care 2017, 33, 552–561. [Google Scholar] [CrossRef] [PubMed]
- Pai, V.V.; Pai, R.B. Artificial Intelligence in Dermatology and Healthcare: An Overview. Indian J. Dermatol. Venereol. Leprol. 2021, 87, 457–467. [Google Scholar] [CrossRef] [PubMed]
- Floridi, L.; Cowls, J.; Beltrametti, M.; Chatila, R.; Chazerand, P.; Dignum, V.; Luetge, C.; Madelin, R.; Pagallo, U.; Rossi, F.; et al. AI4People—An Ethical Framework for a Good AI Society: Opportunities, Risks, Principles, and Recommendations. Minds Mach. 2018, 28, 689–707. [Google Scholar]
- Refolo, P.; Sacchini, D.; Raimondi, C.; Spagnolo, A.G. Ethics of Digital Therapeutics (DTx). Eur. Rev. Med. Pharmacol. Sci. 2022, 26, 6418–6423. [Google Scholar]
- van der Wilt, G.J.; Bloemen, B.; Grin, J.; Gutierrez-Ibarluzea, I.; Sampietro-Colom, L.; Refolo, P.; Sacchini, D.; Hofmann, B.; Sandman, L.; Oortwijn, W. Integrating Empirical Analysis and Normative Inquiry in Health Technology Assessment: The Values in Doing Assessments of Health Technologies Approach. Int. J. Technol. Assess. Health Care 2022, 38, e52. [Google Scholar]
- Craxì, L.; Sacchini, D.; Refolo, P.; Minacori, R.; Daloiso, V.; Ricci, G.; Bruno, R.; Cammà, C.; Cicchetti, A.; Gasbarrini, A.; et al. Prioritization of High-Cost New Drugs for HCV: Making Sustainability Ethical. Eur. Rev. Med. Pharmacol. Sci. 2016, 20, 1044–1051. [Google Scholar]
- Oortwijn, W.; Sampietro-Colom, L. The VALIDATE Handbook; Radboud University Press: Nijmegen, The Netherlands, 2022. [Google Scholar]
- English National Institute for Health and Care Excellence (NICE). NICE Health Technology Evaluations: The Manual. 2023. Available online: https://www.nice.org.uk/process/pmg36/resources/nice-health-technology-evaluations-the-manual-pdf-72286779244741 (accessed on 26 December 2024).
- Canada’s Drug Agency. Methods and Guidelines. Available online: https://www.cda-amc.ca/methods-and-guidelines (accessed on 26 December 2024).
- World Health Organization (WHO). Health Technology Assessment of Medical Devices. 2011. Available online: https://www.who.int/publications/i/item/9789241501361 (accessed on 26 December 2024).
Type of Issue | Context | Question |
---|---|---|
Ethical | Rare diseases | Is the natural history of the disease, its progression, and its long-term effects known? |
Ethical | Rare diseases | Is there any other type of obstacle to evidence generation regarding the benefits and harms of the in-tervention? |
Ethical | Rare diseases | Are there well-established instruments or metrics to assess the efficacy and effectiveness of the technology? |
Ethical | Rare diseases | Does the implementation of technology involve risks of overdiagnosis or underdiagnosis? |
Ethical | Rare diseases | Are there any obstacles to evidence generation regarding the economic evaluation of the intervention? |
Legal | Rare diseases | Is the implementation of the technology associated with issues related to defensive medicine? |
Ethical | AI-based | Does the implementation or use of the technology lead to discrimination due to biased health data? |
Ethical | AI-based | To what extent can the technology provide interpretable and understandable explanations of the reasoning behind its results? |
Ethical | AI-based | How should the environmental impact of the technology be assessed to ensure that its deployment does not disproportionately burden specific populations, regions, or healthcare systems, particularly in terms of energy consumption, resource allocation, and long-term sustainability? |
Legal | AI-based | Is accountability clearly defined in the event that the technology makes a mistake? |
Legal | AI-based | Are the reimbursement policies related to technology implementation well-defined? |
Social | AI-based | When and to what extent will patients be informed about the involvement of AI? |
Social | AI-based | Is the implementation of the technology linked to risks of job losses? |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Refolo, P.; Raimondi, C.; Astratinei, V.; Battaglia, L.; Borràs, J.M.; Closa, P.; Lo Scalzo, A.; Marchetti, M.; Muñoz-López, S.; Sampietro-Colom, L.; et al. Ethical, Legal, and Social Assessment of AI-Based Technologies for Prevention and Diagnosis of Rare Diseases in Health Technology Assessment Processes. Healthcare 2025, 13, 829. https://doi.org/10.3390/healthcare13070829
Refolo P, Raimondi C, Astratinei V, Battaglia L, Borràs JM, Closa P, Lo Scalzo A, Marchetti M, Muñoz-López S, Sampietro-Colom L, et al. Ethical, Legal, and Social Assessment of AI-Based Technologies for Prevention and Diagnosis of Rare Diseases in Health Technology Assessment Processes. Healthcare. 2025; 13(7):829. https://doi.org/10.3390/healthcare13070829
Chicago/Turabian StyleRefolo, Pietro, Costanza Raimondi, Violeta Astratinei, Livio Battaglia, Josep M. Borràs, Paula Closa, Alessandra Lo Scalzo, Marco Marchetti, Sonia Muñoz-López, Laura Sampietro-Colom, and et al. 2025. "Ethical, Legal, and Social Assessment of AI-Based Technologies for Prevention and Diagnosis of Rare Diseases in Health Technology Assessment Processes" Healthcare 13, no. 7: 829. https://doi.org/10.3390/healthcare13070829
APA StyleRefolo, P., Raimondi, C., Astratinei, V., Battaglia, L., Borràs, J. M., Closa, P., Lo Scalzo, A., Marchetti, M., Muñoz-López, S., Sampietro-Colom, L., & Sacchini, D. (2025). Ethical, Legal, and Social Assessment of AI-Based Technologies for Prevention and Diagnosis of Rare Diseases in Health Technology Assessment Processes. Healthcare, 13(7), 829. https://doi.org/10.3390/healthcare13070829